Latest News

PROUD results published showing pre-exposure prophylaxis effectively prevents HIV


10 September 2015

Results from the PROUD study, showing a daily pill can effectively protect people from HIV infection, were published today in The Lancet. PROUD is the first study of the pre-exposure prophylaxis approach to preventing HIV to be carried out in the UK. The results show the approach could play a major role in reducing the number of new infections among men who have sex with men.

Pre-exposure prophylaxis (PrEP) is a HIV prevention strategy that involves HIV-negative people taking antiretroviral drugs to reduce the risk of becoming infected if they are exposed to the virus. The PROUD study looked at whether offering daily PrEP to men who have sex with men was an effective way to prevent HIV infection.  The results show that PrEP is highly protective, reducing the risk of infection for this group by 86%.

Read more

Study Results

24 February 2015

The PROUD study today reported that PrEP reduced the risk of HIV infection by 86% for gay and other men who have sex with men when delivered in sexual health clinics in England.

The PROUD study measured the effectiveness of daily PrEP for gay and other men who have sex with men in England.  The results released at the Conference on Retroviruses and Opportunistic Infections today indicate that PrEP is highly protective for this group, reducing the risk of infection by 86%. The researchers concluded that PrEP offers a major opportunity to curb new HIV infections in men who have sex with men in the UK.

Read more


The PROUD Study

Examining the impact on gay men of using Pre-Exposure Prophylaxis (PrEP)

What is PrEP?

PrEP (Pre-Exposure Prophylaxis) is a new way to reduce the risk of getting HIV. It involves HIV negative people taking a daily tablet that contains drugs commonly used to treat HIV.

PROUD is a two-year study to recruit volunteers across England, who will be placed at random into one of two groups. One group will use PrEP from the start of the study, and the other group will receive PrEP after 12 months.

Truvada (which contains tenofovir and emtricitabine, also called FTC) is used in this study. Truvada is already widely used and any side effects are usually mild.

Previous studies with gay men found that using PrEP almost halved HIV infections – and there were even fewer infections amongst men who took their pill every day.

Other News

PROUD trial documentary: 

The world premiere screening of the PROUD documentary took place in London on 1st July 2015. It has also been shown in Birmingham, Brighton, East London and Hamburg. Thank you to those who organised, hosted and attended these events.

Watch the PROUD documentary here:

Further screenings to be scheduled soon at various UK/international locations. Click here to see listings.

Read more

If you would like to receive updates on the development of a research agenda around PrEP including future PrEP studies and on the development of a PrEP policy in the UK, sign up to the new MRC CTU at UCL PrEP Update mailing list by sending an email to:


19 January 2014


Given that the PROUD pilot study has answered the important question of how much protection daily Truvada can offer when provided in sexual health clinics in the UK, there is no need for the planned larger clinical trial. As such, we have withdrawn our funding application to reopen the PROUD study for new recruitment.

Read more

                  - - - - - -

Trial participants can now use a mobile format to complete their diary and questionnaires.            This can be found at

HIV charities release joint statement on PrEP

A group of the UK’s leading HIV charities have released a joint statement outlining their position on Pre-Exposure Prophylaxis (PrEP). Read more


Recruitment has been running since November 2012 and 544 men have been recruited from the UK clinics listed below. Recruitment to the pilot is now complete.


The PROUD study has recruited in:

  • London (8 sites)
  • Brighton
  • Birmingham
  • York
  • Manchester
  • Sheffield

For participating clinic address/contact information, please [click here].